A modified FLOT regimen (fluorouracil, oxaliplatin, and docetaxel; TFOX) outperformed a standard chemotherapy triplet for the ...

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic ...

Comparing capecitabine as the fluoropyrimidine component in combination with oxaliplatin (XELOX) in the second-line setting in metastatic colorectal cancer to an infusional combination of 5 ...

The pivotal trials on first-line FOLFOX and FOLFIRI demonstrated a ... but still eligible for aggressive chemotherapy were included. The IROX results cannot, therefore, be generalized to patients ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPN Preclinical data show ...